98%
921
2 minutes
20
Objective: Minimally invasive combined mitral and aortic valve surgery is still uncommon. We report our experience performing multiple valve procedures through a right-sided minithoracotomy.
Methods: We present an observational case series with a retrospective analysis of 38 patients who underwent double valve surgery through right anterior thoracotomy from November 2013 to November 2023.
Results: The median age of our population was 72 years, and 61% were female patients. The median EuroSCORE II was 2.27. Three patients (7.9%) had redo operations. The median cardiopulmonary bypass (CPB) and cross-clamp times were 98 and 85 min, respectively. No conversion to full sternotomy was necessary. In-hospital mortality was 2.6% (1 patient); the patient died of septic shock and consequent multiorgan failure. Of the patients, 53% required transfusions with packed blood cells. Postoperative atrial fibrillation was observed in 12 patients (32%), and 2 patients (5.2%) required pacemaker implantation due to third-degree atrioventricular block. Also, 1 stroke (2.6%) and 1 rethoracotomy for bleeding were observed. The median ventilation time was 10 h. The median intensive care unit and postoperative length of stay were 2 days and 7.5 days, respectively. Survival at 1, 3, 5, and 10 years was 93.8%, 86.3%, 86.3%, and 77.2%, respectively, with a median follow-up time of 6.5 years. Freedom from reintervention at 1, 3, 5, and 10 years was 96.8%, 89.5%, 85.0%, and 69.5%, respectively, with a median follow-up time of 5.7 years.
Conclusions: In our experience, a minimally invasive approach for combined aortic and mitral valve surgery is safe and feasible, with acceptable CPB and cross-clamp times and good outcomes. Therefore, it can be an attractive option for patients with double valve diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/15569845251314025 | DOI Listing |
J Am Coll Cardiol
September 2025
Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiologic Sciences and Public Health, University of Brescia, Brescia, Italy. Electronic address:
Secondary mitral regurgitation (SMR) is common in patients with heart failure (HF). Although randomized clinical trials have been focused on the treatment of severe SMR, the prognostic role and potential for treatment of moderate SMR cannot be overlooked. The randomized RESHAPE-HF2 trial included patients with moderate and severe SMR with consistent findings in both groups, raising the hypothesis that transcatheter correction of moderate SMR could have beneficial effects, although this needs further investigation.
View Article and Find Full Text PDFPediatrics
September 2025
Department of Pediatrics, Section of Cardiology, Arkansas Children's Hospital, Little Rock, Arkansas.
Surgical innovation spans a spectrum from minor modifications of existing procedures to the development of new procedures. Surgeons routinely innovate at the lower end of this spectrum to adapt standardized procedures to the unique needs of individual patients. These innovations can be made at the surgeon's discretion without external oversight because they form part of clinical practice.
View Article and Find Full Text PDFJ Pediatr Surg
September 2025
University of Utah, Department of Surgery, Division of Pediatric Surgery. Electronic address:
Background: Routine preoperative echocardiograms (ECHOs) are frequently obtained in patients undergoing minimally invasive repair of pectus excavatum (MIRPE), but the benefit and necessity of preoperative screening remain debated. In this study, we sought to quantify the proportion of preoperative ECHOs that had clinically significant findings.
Methods: We conducted a retrospective review of 255 patients who underwent MIRPE at a single pediatric referral center from 2018 to 2023.
J Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.
J Invasive Cardiol
September 2025
Division of Cardiology, Mount Sinai Heart Fuster Hospital, Icahn School of Medicine at Mount Sinai, New York, New York. Email: